ZuraPrep™ is a presurgical skin preparation for the prevention of surgical site infections. There are approximately 27 million to 32 million surgical procedures each year in the US. The CDC estimates that there are 500,000 surgical site infections (SSI) each year. SSI results in an average increase of 7.3 days to a post-operative hospital stay and annual attributable costs are $1.5 billion.
The size of the SSI preoperative skin prep treatment market is approximately $500 million in the US alone. There are multiple products currently approved for use, most of which consist either of povidone iodine + alcohol or chlorhexidine + alcohol. There has been virtually no innovation in this market for over a decade.
ZuraPrep™ was formulated from the Zurex antimicrobial technology platform and designed to be a safe and effective presurgical skin preparation. Pilot clinical testing on 36 patients in a controlled setting, under the latest FDA TFM protocol requirements, demonstrated efficacy results which significantly exceeded FDA's targets for market approval and there were no observable or reported safety issues. Zurex management believes ZuraPrep™ has a significant opportunity to clinically outperform the current market leading products and drive additional value and differentiation through a patent protected compound and applicator.
New Ag Products
ZuraLac™ is specifically formulated to sanitize and protect teats from mastitis causing organisms, and protect teat skin tissue from harsh environmental conditions.
Zurex Pharma's corporate office is located in the Middleton Industrial Park. Specific comments or questions may be submitted online through our contact page.